• Streptavidin-Cy3 for Spatial Metastasis Biology

  2026-09-14

  Learn how Streptavidin-Cy3 converts biotinylated probes and antibodies into spatially resolved evidence for metastasis research. This article connects super-enhancer RNA biology with rigorous fluorescence assay design, controls, and interpretation.

• Reactive Oxygen Species Assay Kit for Cancer ROS

  2026-09-14

  Turn treatment-induced redox changes into quantitative live-cell data with a DCFH-DA workflow built for cancer and nanomedicine experiments. The assay pairs a defined positive control with practical normalization and troubleshooting strategies for distinguishing genuine oxidative responses from probe, plate, or particle artifacts.

• Isochlorogenic acid A: Hydrogel Research Workflow

  2026-09-13

  Learn how Isochlorogenic acid A can support solvent-aware natural product assays and formulation-led wound-repair studies. This workflow connects 3,5-Dicaffeoylquinic acid handling with antibacterial, cell-migration, inflammation, and hydrogel performance readouts while distinguishing published findings from practical optimization steps.

• MG-132 as a Probe of Viral Immune Evasion

  2026-09-12

  MG-132 is more than a proteasome inhibitor for apoptosis assays: it can serve as a controlled perturbation of host protein turnover. This article connects MG-132 mechanistic workflows with the UL88–MyD88 immune-evasion axis in HCMV while defining the limits of pharmacological inference.

• Mecamylamine Hydrochloride in Cholinergic Assays

  2026-09-11

  Mecamylamine hydrochloride provides a brain-penetrant, non-competitive way to test whether nicotinic signaling contributes to cellular, behavioral, or gut-brain phenotypes. This workflow connects receptor pharmacology with vagal and epilepsy models while emphasizing controls, solvent handling, and interpretation limits.

• Potassium Channels and Renal Blood Flow in Sepsis

  2026-09-11

  This rat study shows that renal potassium-channel blockade can worsen vasopressor-associated reductions in renal blood flow during sepsis, even when the blockers do not alter baseline flow. Its key contribution is the distinction between ex vivo vascular reactivity and in vivo renal perfusion, demonstrating that Kir6.1 and KCa1.1 channels help preserve renal vascular reserve during septic shock.

• Rethinking In Vitro Cancer Drug Response Metrics

  2026-09-10

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but not interchangeable drug-response outcomes. This framework encourages time-aware, mechanistically aligned in vitro experiments and provides a more rigorous basis for interpreting apoptosis-focused cancer studies.

• GM 6001 (Galardin) for ECM Research

  2026-09-10

  GM 6001, also called Galardin, provides a nanomolar-potency approach for testing MMP-driven extracellular matrix remodeling. This workflow-focused guide connects perineuronal-net biology with meniscal healing research, EGFR signaling, cancer cell proliferation modulation, and vascular smooth muscle cell migration inhibition.

• Structure-Guided Proteomimetics for SARS-CoV-2 Entry

  2026-09-09

  The reference study uses structure-guided alanine mutagenesis and conformational constraint to build proteomimetics that reproduce key hACE2 contact elements at the SARS-CoV-2 Spike RBD interface. Its lead construct, compound 28, disrupted RBD–hACE2 binding, inhibited pseudovirus entry, and showed lung-epithelial stability and low permeability that support further evaluation for intranasal delivery.

• Calcitriol in VDR and Cell Assays

  2026-09-09

  Calcitriol enables mechanism-focused studies spanning VDR-dependent endometrial decidualization, cytokine regulation, and Hedgehog pathway biology. This workflow-centered guide shows how to prepare, dose, validate, and troubleshoot Calcitriol assays without confusing pathway activation with downstream clinical effects.

• AG-221 and the Metabolic Logic of IDH2 AML

  2026-09-09

  IDH2-mutant leukemia is sustained not only by aberrant 2-hydroxyglutarate production but also by metabolic programs that support it. This thought-leadership analysis connects AG-221 (Enasidenib) to CD44-dependent metabolic rewiring and translates that biology into practical, biomarker-led workflows for acute myeloid leukemia research.

• HyperScript RT SuperMix for qPCR: cDNA

  2026-09-08

  HyperScript RT SuperMix for qPCR is a 5X premixed solution for two-step qRT-PCR cDNA synthesis. Its engineered HyperScript Reverse Transcriptase, mixed-primer design, and high RNA-volume tolerance address structured and low-concentration RNA workflows without implying that reverse transcription alone proves a biological mechanism.

• Protease Inhibitor Cocktail for DFCP1–ATGL Assays

  2026-09-07

  Protect DFCP1–ATGL interactions, lipid-droplet fractions, and starvation-sensitive lysates from post-lysis degradation with an EDTA-aware extraction strategy. This workflow combines broad-spectrum inhibition with practical safeguards for co-immunoprecipitation, Western blotting, kinase assays, and downstream protein purification.

• Exosomal miR-519d-3p and Immune Dysregulation in Preeclampsi

  2026-09-07

  The reference study links elevated placenta-derived exosomal miR-519d-3p with altered Jurkat T-cell survival, proliferation, and Th17/Treg differentiation in preeclampsia. Its main contribution is a functional in vitro framework connecting placental extracellular-vesicle cargo with immune intolerance, while also highlighting the limits of transformed-cell models for explaining maternal disease.

• ampC/ampD Mutations in P. aeruginosa Resistance

  2026-09-05

  Deroche and colleagues used isogenic mutants, sequential time-kill experiments, and semi-mechanistic PKPD modeling to separate the initial and adaptive effects of ampC and ampD mutations on ceftolozane-tazobactam resistance. The study shows that the combined AmpC G183D and AmpD H157Y genotype produces a substantially stronger resistance phenotype than either mutation alone, while also altering imipenem susceptibility.

8568 records 1/572 page Next 12345 下5页 Last page